Clobazam in therapy-resistant patients with partial epilepsy: A double-blind placebo-controlled crossover study

D. Koeppen, A. Baruzzi, M. Capozza, P. Chauvel, J. Courjon, P. Favel, J. Harmant, H. Lorenz, F. V L Oller, G. Procaccianti, M. Rucquoy-Ponsar, C. Sallou, G. Sideri, S. Trottier, M. Weber, P. Wolf

Research output: Contribution to journalArticle

Abstract

Clobazam was compared with placebo as antiepileptic adjunct medication in 129 therapy-resistant epileptic patients who were mainly suffering from complex partial seizures. The study was performed in five European countries according to a double-blind crossover design lasting 7 months. Two treatment periods of 3 months (1 month adjustment and 2 months maintenance medication) were separated by one medication switch-over month. The difference in seizure reduction between clobazam and placebo was significant (p <0.05). Nineteen percent of patients receiving clobazam became seizure-free during the maintenance dose period. In contrast, freedom from seizures was not observed in any placebo patient. Electroencephalogram (EEG) signs, mood ratings, and global impressions also indicated therapeutic effects of clobazam in epilepsy. The most frequent adverse reactions to clobazam were drowsiness and dizziness. However, the sedative effects of clobazam seemed to be less pronounced in comparison with other benzodiazepines. The study gives evidence of the therapeutic value of clobazam as adjunct medication in therapy-resistant partial seizures. The use of clobazam as monotherapy and long-term treatment, as well as the particular seizure response pattern to clobazam, has to be further investigated.

Original languageEnglish
Pages (from-to)495-506
Number of pages12
JournalEpilepsia
Volume28
Issue number5
Publication statusPublished - 1987

Fingerprint

Partial Epilepsy
Cross-Over Studies
Placebos
Seizures
Therapeutics
Social Adjustment
clobazam
Sleep Stages
Dizziness
Therapeutic Uses
Hypnotics and Sedatives
Benzodiazepines
Anticonvulsants
Electroencephalography
Epilepsy
Maintenance

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Koeppen, D., Baruzzi, A., Capozza, M., Chauvel, P., Courjon, J., Favel, P., ... Wolf, P. (1987). Clobazam in therapy-resistant patients with partial epilepsy: A double-blind placebo-controlled crossover study. Epilepsia, 28(5), 495-506.

Clobazam in therapy-resistant patients with partial epilepsy : A double-blind placebo-controlled crossover study. / Koeppen, D.; Baruzzi, A.; Capozza, M.; Chauvel, P.; Courjon, J.; Favel, P.; Harmant, J.; Lorenz, H.; Oller, F. V L; Procaccianti, G.; Rucquoy-Ponsar, M.; Sallou, C.; Sideri, G.; Trottier, S.; Weber, M.; Wolf, P.

In: Epilepsia, Vol. 28, No. 5, 1987, p. 495-506.

Research output: Contribution to journalArticle

Koeppen, D, Baruzzi, A, Capozza, M, Chauvel, P, Courjon, J, Favel, P, Harmant, J, Lorenz, H, Oller, FVL, Procaccianti, G, Rucquoy-Ponsar, M, Sallou, C, Sideri, G, Trottier, S, Weber, M & Wolf, P 1987, 'Clobazam in therapy-resistant patients with partial epilepsy: A double-blind placebo-controlled crossover study', Epilepsia, vol. 28, no. 5, pp. 495-506.
Koeppen D, Baruzzi A, Capozza M, Chauvel P, Courjon J, Favel P et al. Clobazam in therapy-resistant patients with partial epilepsy: A double-blind placebo-controlled crossover study. Epilepsia. 1987;28(5):495-506.
Koeppen, D. ; Baruzzi, A. ; Capozza, M. ; Chauvel, P. ; Courjon, J. ; Favel, P. ; Harmant, J. ; Lorenz, H. ; Oller, F. V L ; Procaccianti, G. ; Rucquoy-Ponsar, M. ; Sallou, C. ; Sideri, G. ; Trottier, S. ; Weber, M. ; Wolf, P. / Clobazam in therapy-resistant patients with partial epilepsy : A double-blind placebo-controlled crossover study. In: Epilepsia. 1987 ; Vol. 28, No. 5. pp. 495-506.
@article{0fdb7f630f6442968655102bc3141e84,
title = "Clobazam in therapy-resistant patients with partial epilepsy: A double-blind placebo-controlled crossover study",
abstract = "Clobazam was compared with placebo as antiepileptic adjunct medication in 129 therapy-resistant epileptic patients who were mainly suffering from complex partial seizures. The study was performed in five European countries according to a double-blind crossover design lasting 7 months. Two treatment periods of 3 months (1 month adjustment and 2 months maintenance medication) were separated by one medication switch-over month. The difference in seizure reduction between clobazam and placebo was significant (p <0.05). Nineteen percent of patients receiving clobazam became seizure-free during the maintenance dose period. In contrast, freedom from seizures was not observed in any placebo patient. Electroencephalogram (EEG) signs, mood ratings, and global impressions also indicated therapeutic effects of clobazam in epilepsy. The most frequent adverse reactions to clobazam were drowsiness and dizziness. However, the sedative effects of clobazam seemed to be less pronounced in comparison with other benzodiazepines. The study gives evidence of the therapeutic value of clobazam as adjunct medication in therapy-resistant partial seizures. The use of clobazam as monotherapy and long-term treatment, as well as the particular seizure response pattern to clobazam, has to be further investigated.",
author = "D. Koeppen and A. Baruzzi and M. Capozza and P. Chauvel and J. Courjon and P. Favel and J. Harmant and H. Lorenz and Oller, {F. V L} and G. Procaccianti and M. Rucquoy-Ponsar and C. Sallou and G. Sideri and S. Trottier and M. Weber and P. Wolf",
year = "1987",
language = "English",
volume = "28",
pages = "495--506",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Blackwell Publishing Inc.",
number = "5",

}

TY - JOUR

T1 - Clobazam in therapy-resistant patients with partial epilepsy

T2 - A double-blind placebo-controlled crossover study

AU - Koeppen, D.

AU - Baruzzi, A.

AU - Capozza, M.

AU - Chauvel, P.

AU - Courjon, J.

AU - Favel, P.

AU - Harmant, J.

AU - Lorenz, H.

AU - Oller, F. V L

AU - Procaccianti, G.

AU - Rucquoy-Ponsar, M.

AU - Sallou, C.

AU - Sideri, G.

AU - Trottier, S.

AU - Weber, M.

AU - Wolf, P.

PY - 1987

Y1 - 1987

N2 - Clobazam was compared with placebo as antiepileptic adjunct medication in 129 therapy-resistant epileptic patients who were mainly suffering from complex partial seizures. The study was performed in five European countries according to a double-blind crossover design lasting 7 months. Two treatment periods of 3 months (1 month adjustment and 2 months maintenance medication) were separated by one medication switch-over month. The difference in seizure reduction between clobazam and placebo was significant (p <0.05). Nineteen percent of patients receiving clobazam became seizure-free during the maintenance dose period. In contrast, freedom from seizures was not observed in any placebo patient. Electroencephalogram (EEG) signs, mood ratings, and global impressions also indicated therapeutic effects of clobazam in epilepsy. The most frequent adverse reactions to clobazam were drowsiness and dizziness. However, the sedative effects of clobazam seemed to be less pronounced in comparison with other benzodiazepines. The study gives evidence of the therapeutic value of clobazam as adjunct medication in therapy-resistant partial seizures. The use of clobazam as monotherapy and long-term treatment, as well as the particular seizure response pattern to clobazam, has to be further investigated.

AB - Clobazam was compared with placebo as antiepileptic adjunct medication in 129 therapy-resistant epileptic patients who were mainly suffering from complex partial seizures. The study was performed in five European countries according to a double-blind crossover design lasting 7 months. Two treatment periods of 3 months (1 month adjustment and 2 months maintenance medication) were separated by one medication switch-over month. The difference in seizure reduction between clobazam and placebo was significant (p <0.05). Nineteen percent of patients receiving clobazam became seizure-free during the maintenance dose period. In contrast, freedom from seizures was not observed in any placebo patient. Electroencephalogram (EEG) signs, mood ratings, and global impressions also indicated therapeutic effects of clobazam in epilepsy. The most frequent adverse reactions to clobazam were drowsiness and dizziness. However, the sedative effects of clobazam seemed to be less pronounced in comparison with other benzodiazepines. The study gives evidence of the therapeutic value of clobazam as adjunct medication in therapy-resistant partial seizures. The use of clobazam as monotherapy and long-term treatment, as well as the particular seizure response pattern to clobazam, has to be further investigated.

UR - http://www.scopus.com/inward/record.url?scp=0023206004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023206004&partnerID=8YFLogxK

M3 - Article

C2 - 3115770

AN - SCOPUS:0023206004

VL - 28

SP - 495

EP - 506

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - 5

ER -